FDA Approved: EPCLUSA — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Epclusa (velpatasvir/sofosbuvir) from Gilead Sciences, expanding its approved uses for hepatitis C treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Epclusa (sofosbuvir/velpatasvir)

Snippet

SUPPL AP for EPCLUSA (VELPATASVIR AND SOFOSBUVIR)